With the explosion of data-intensive research tools, pharmaceutical companies are still struggling to understand how to most effectively make use of them. This package has the first few of a series of interviews with pharmaceutical executives about how are beginning to use genomics to enhance their drug discovery pipelines. It examines the usefulness of microarrays, proteomics, genotyping, RNAi and other genomic tools. It includes interviews from top executives with Pfizer, GlaxoSmithKline, Astrazeneca, and Merck.
Read the full story at Bio-IT World